<VariationArchive VariationID="182957" VariationName="NM_000546.6(TP53):c.216dup (p.Val73fs)" VariationType="Duplication" Accession="VCV000182957" Version="16" RecordType="classified" NumberOfSubmissions="10" NumberOfSubmitters="9" DateLastUpdated="2024-05-08" DateCreated="2013-04-04" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="181025" VariationID="182957">
      <GeneList>
        <Gene Symbol="TP53" FullName="tumor protein p53" GeneID="7157" HGNC_ID="HGNC:11998" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7668421" stop="7687490" display_start="7668421" display_stop="7687490" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7571719" stop="7590867" display_start="7571719" display_stop="7590867" Strand="-" />
          </Location>
          <OMIM>191170</OMIM>
          <Haploinsufficiency last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TP53">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000546.6(TP53):c.216dup (p.Val73fs)</Name>
      <CanonicalSPDI>NC_000017.11:7676152:GGGGGG:GGGGGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>17p13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="7579470" stop="7579471" display_start="7579470" display_stop="7579471" variantLength="1" positionVCF="7579470" referenceAlleleVCF="C" alternateAlleleVCF="CG" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="7676152" stop="7676153" display_start="7676152" display_stop="7676153" variantLength="1" positionVCF="7676152" referenceAlleleVCF="C" alternateAlleleVCF="CG" />
      </Location>
      <ProteinChange>V34fs</ProteinChange>
      <ProteinChange>V73fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.7579476dup" Assembly="GRCh37">
            <Expression>NC_000017.10:g.7579476dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.7676158dup" Assembly="GRCh38">
            <Expression>NC_000017.11:g.7676158dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_017013.2" sequenceAccession="NG_017013" sequenceVersion="2" change="g.16398dup">
            <Expression>NG_017013.2:g.16398dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000546.6" sequenceAccession="NM_000546" sequenceVersion="6" change="c.216dup" MANESelect="true">
            <Expression>NM_000546.6:c.216dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000537.3" sequenceAccession="NP_000537" sequenceVersion="3" change="p.Val73fs">
            <Expression>NP_000537.3:p.Val73fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126112.3" sequenceAccession="NM_001126112" sequenceVersion="3" change="c.216dup">
            <Expression>NM_001126112.3:c.216dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119584.1" sequenceAccession="NP_001119584" sequenceVersion="1" change="p.Val73fs">
            <Expression>NP_001119584.1:p.Val73fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126113.3" sequenceAccession="NM_001126113" sequenceVersion="3" change="c.216dup">
            <Expression>NM_001126113.3:c.216dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119585.1" sequenceAccession="NP_001119585" sequenceVersion="1" change="p.Val73fs">
            <Expression>NP_001119585.1:p.Val73fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126114.3" sequenceAccession="NM_001126114" sequenceVersion="3" change="c.216dup">
            <Expression>NM_001126114.3:c.216dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119586.1" sequenceAccession="NP_001119586" sequenceVersion="1" change="p.Val73fs">
            <Expression>NP_001119586.1:p.Val73fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126118.2" sequenceAccession="NM_001126118" sequenceVersion="2" change="c.99dup">
            <Expression>NM_001126118.2:c.99dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119590.1" sequenceAccession="NP_001119590" sequenceVersion="1" change="p.Val34fs">
            <Expression>NP_001119590.1:p.Val34fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276695.3" sequenceAccession="NM_001276695" sequenceVersion="3" change="c.99dup">
            <Expression>NM_001276695.3:c.99dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263624.1" sequenceAccession="NP_001263624" sequenceVersion="1" change="p.Val34fs">
            <Expression>NP_001263624.1:p.Val34fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276696.3" sequenceAccession="NM_001276696" sequenceVersion="3" change="c.99dup">
            <Expression>NM_001276696.3:c.99dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263625.1" sequenceAccession="NP_001263625" sequenceVersion="1" change="p.Val34fs">
            <Expression>NP_001263625.1:p.Val34fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276760.3" sequenceAccession="NM_001276760" sequenceVersion="3" change="c.99dup">
            <Expression>NM_001276760.3:c.99dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263689.1" sequenceAccession="NP_001263689" sequenceVersion="1" change="p.Val34fs">
            <Expression>NP_001263689.1:p.Val34fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276761.3" sequenceAccession="NM_001276761" sequenceVersion="3" change="c.99dup">
            <Expression>NM_001276761.3:c.99dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263690.1" sequenceAccession="NP_001263690" sequenceVersion="1" change="p.Val34fs">
            <Expression>NP_001263690.1:p.Val34fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_321" sequenceAccession="LRG_321">
            <Expression>LRG_321:g.16398dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000546.5" sequenceAccession="NM_000546" sequenceVersion="5" change="c.216dupC">
            <Expression>NM_000546.5:c.216dupC</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000546.4" sequenceAccession="NM_000546" sequenceVersion="4" change="c.216dupC">
            <Expression>NM_000546.4:c.216dupC</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_321t1" sequenceAccession="LRG_321t1">
            <Expression>LRG_321t1:c.216dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA000073" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="191170.0016" DB="OMIM" />
        <XRef Type="rs" ID="730882018" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000546.6(TP53):c.216dup (p.Val73fs) AND Li-fraumeni-like syndrome" Accession="RCV000013157" Version="21">
        <ClassifiedConditionList TraitSetID="9229">
          <ClassifiedCondition DB="MedGen" ID="C2675080">Li-fraumeni-like syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1995-01-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.216dup (p.Val73fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000161059" Version="7">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-06-18" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.216dup (p.Val73fs) AND Li-Fraumeni syndrome" Accession="RCV000538223" Version="8">
        <ClassifiedConditionList TraitSetID="2589">
          <ClassifiedCondition DB="MedGen" ID="C0085390">Li-Fraumeni syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.216dup (p.Val73fs) AND Multiple myeloma" Accession="RCV000984104" Version="2">
        <ClassifiedConditionList TraitSetID="6478">
          <ClassifiedCondition DB="MedGen" ID="C0026764">Multiple myeloma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2019-08-31" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.216dup (p.Val73fs) AND Breast and/or ovarian cancer" Accession="RCV001798560" Version="3">
        <ClassifiedConditionList TraitSetID="20192">
          <ClassifiedCondition DB="MedGen" ID="CN221562">Breast and/or ovarian cancer</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-05-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000546.6(TP53):c.216dup (p.Val73fs) AND Li-Fraumeni syndrome 1" Accession="RCV002288698" Version="3">
        <ClassifiedConditionList TraitSetID="3343">
          <ClassifiedCondition DB="MedGen" ID="C1835398">Li-Fraumeni syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-02-12" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-12" NumberOfSubmissions="10" NumberOfSubmitters="9" DateCreated="2013-04-04" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1565143</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20522432</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28369373</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8718514</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3343" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5406" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome 1</ElementValue>
                <XRef ID="C538639" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">LFS1</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
                <XRef Type="MIM" ID="151623" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2009">
                <ID Source="pmc">2668639</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASHG/ACMG, 1995">
                <ID Source="pmc">1801355</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASHG/ACMG, 2015">
                <ID Source="PubMed">26140447</ID>
                <ID Source="pmc">4570999</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="553989" DB="Gene" />
              <XRef ID="C1835398" DB="MedGen" />
              <XRef Type="MIM" ID="151623" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="20192" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32337" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Breast and/or ovarian cancer</ElementValue>
                <XRef ID="UWMG_7622958" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <XRef ID="CN221562" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9229" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="8533" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-fraumeni-like syndrome</ElementValue>
                <XRef ID="MONDO:0800290" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">LFL</ElementValue>
                <XRef ID="151623" DB="OMIM" />
              </Symbol>
              <XRef ID="C2675080" DB="MedGen" />
              <XRef ID="MONDO:0800290" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6478" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="3136" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Multiple myeloma</ElementValue>
                <XRef ID="Multiple+myeloma/4962" DB="Genetic Alliance" />
                <XRef ID="HP:0006775" DB="Human Phenotype Ontology" />
                <XRef ID="109989006" DB="SNOMED CT" />
                <XRef ID="55921005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Plasma cell myeloma</ElementValue>
                <XRef ID="MONDO:0009693" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kahler disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Myelomatosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Plasma cell dyscrasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Multiple myeloma, somatic</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MM</ElementValue>
                <XRef ID="GTR000500644" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7108" />
                <XRef ID="7108" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®) Multiple Myeloma, 2023</CitationText>
              </Citation>
              <XRef ID="29073" DB="Orphanet" />
              <XRef ID="85443" DB="Orphanet" />
              <XRef ID="C0026764" DB="MedGen" />
              <XRef ID="D009101" DB="MeSH" />
              <XRef ID="MONDO:0009693" DB="MONDO" />
              <XRef Type="MIM" ID="254500" DB="OMIM" />
              <XRef Type="primary" ID="HP:0006775" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2589" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10539" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Li-Fraumeni syndrome</ElementValue>
                <XRef ID="MONDO:0018875" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
                <XRef ID="428850001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sarcoma family syndrome of Li and Fraumeni</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">LFS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6902" />
                <XRef ID="6902" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with high risks for a diverse spectrum of childhood- and adult-onset malignancies. The lifetime risk of cancer in individuals with LFS is =70% for men and =90% for women. Five cancer types account for the majority of LFS tumors: adrenocortical carcinomas, breast cancer, central nervous system tumors, osteosarcomas, and soft-tissue sarcomas. LFS is associated with an increased risk of several additional cancers including leukemia, lymphoma, gastrointestinal cancers, cancers of head and neck, kidney, larynx, lung, skin (e.g., melanoma), ovary, pancreas, prostate, testis, and thyroid. Individuals with LFS are at increased risk for cancer in childhood and young adulthood; survivors are at increased risk for multiple primary cancers.</Attribute>
                <XRef ID="NBK1311" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301488</ID>
                <ID Source="BookShelf">NBK1311</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="524" DB="Orphanet" />
              <XRef ID="C0085390" DB="MedGen" />
              <XRef ID="MONDO:0018875" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS151623" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="33404" SubmissionDate="2013-04-09" DateLastUpdated="2013-04-04" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="191170.0016_LI-FRAUMENI-LIKE SYNDROME" title="TP53, 1-BP INS, CODONS 71-72_LI-FRAUMENI-LIKE SYNDROME" />
        <ClinVarAccession Accession="SCV000033404" DateUpdated="2013-04-04" DateCreated="2013-04-04" Type="SCV" Version="1" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1995-01-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Toguchida et al. (1992) identified an insertion of 1 cytosine in a stretch of 6 cytosines spanning codons 71 and 72 of the p53 gene in a girl who died at the age of 15 of osteosarcoma. The mother had died at age 25 years of a brain tumor. Eeles (1995) classified this family as having Li-Fraumeni-like syndrome (see 151623).</Attribute>
              <Citation>
                <ID Source="PubMed">1565143</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">8718514</ID>
              </Citation>
              <XRef DB="OMIM" ID="151623" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <Name>TP53, 1-BP INS, CODONS 71-72</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, CODONS 71-72</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="191170.0016" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">LI-FRAUMENI-LIKE SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4007350" SubmissionDate="2021-12-23" DateLastUpdated="2021-12-29" DateCreated="2021-12-29">
        <ClinVarSubmissionID localKey="302812|MedGen:CN221562" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002042826" DateUpdated="2021-12-29" DateCreated="2021-12-29" Type="SCV" Version="1" SubmitterName="CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario" OrgID="1050" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.5:c.216dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN221562" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10844479</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="511639" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2015-02-24">
        <ClinVarSubmissionID localKey="a86046|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000275185" DateUpdated="2024-05-01" DateCreated="2015-02-24" Type="SCV" Version="8" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.216dupC pathogenic mutation, located in coding exon 3 of the TP53 gene, results from a duplication of C at nucleotide position 216, causing a translational frameshift with a predicted alternate stop codon (p.V73Rfs*76). In one study, this mutation was reported in the germline of a patient with osteosarcoma at age 15y, whose mother had breast cancer at age 25y (Toguchida J et al. N Engl J Med. 1992;326(20):130-18). This mutation has also been detected in a breast cancer patient diagnosed at age 27y and an unaffected 28y/o male. Functional studies demonstrated an ~50% decrease in p53 functionality score of lymphocytes as compared to wildtype (Zerdoumi Y et al. Hum Mol Genet. 2017 Jul 15;26(14):2812). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.4:c.216dupC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="377492" SubmissionDate="2015-02-05" DateLastUpdated="2015-02-24" DateCreated="2015-02-24">
        <ClinVarSubmissionID localKey="62679" />
        <ClinVarAccession Accession="SCV000211791" DateUpdated="2015-02-24" DateCreated="2015-02-24" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-09-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This duplication of one nucleotide in TP53 is denoted c.216_217insC (aka c.216dupC) at the cDNA level and p.Val73ArgfsX76 (V73RfsX76) at the protein level. The normal sequence, with the bases that are inserted in brackets, is TCCCCCC[C]GTGG. The duplication causes a frameshift, which changes a Valine to an Arginine at codon 73 in exon 4, and creates a premature stop codon at position 76 of the new reading frame. This mutation is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. TP53 c.216_217insC has been observed in an individual with osteosarcoma with a family history of early-onset breast cancer (Toguchida 1992). We consider this mutation to be pathogenic. Mosaicism for TP53 mutations has been reported in at least three patients, all of whom had cancer themselves and none of whom had a family history significant for Li Fraumeni syndrome (Prochazkova 2009, Walsh 2011, Mitchell 2013). A pathogenic mutation in this gene is indicative of Li-Fraumeni syndrome (LFS), an autosomal dominant condition associated with a high-risk for a broad range of childhood- and adult-onset cancers. The following core cancer types account for 70-77% of LFS-associated tumors (in order of frequency): breast cancer, soft tissue sarcoma, brain tumors, osteosarcoma, and adrenocortical carcinoma (Gonzalez 2009, Olivier 2003, Ruijs 2010). Other types of cancer that have been reported to be associated with LFS include ovarian, gastrointestinal, pancreatic, genitourinary, skin, thyroid and lung cancers as well as leukemia, lymphoma, and neuroblastomas. Age-related and sex-specific cancer risks have been reported. According to one study, the overall risks for males with LFS to develop cancer by ages 16, 45, and 85 are estimated to be 19%, 41%, and 73%, respectively, whereas the risks for females are estimated to be 12%, 84%, and 100%, respectively (Chompret 2000). The higher penetrance in females is due to the high incidence of breast cancer, accounting for 80% of the cancers in the age group of 16 to 45 years (Chompret 2000). The majority of LFS-associated breast cancers are HER2/neu positive ductal carcinomas (Melhem-Bertrandt 2012). The most common types of sarcomas in LFS are rhabdomyosarcomas before age 5 and osteosarcomas at any age (Ognjanovic 2012). LFS is associated with many types of brain tumors including astrocytomas, glioblastomas, medulloblastomas and choroid plexus carcinomas, and they can occur in childhood or adulthood (Olivier 2003). Individuals with LFS who have been diagnosed with cancer have up to a 57% risk of a second primary cancer within 30 years of the first diagnosis and up to a 38% risk of a third primary diagnosis (Hisada 1998). Several studies have demonstrated that subsequent tumors often develop in the radiation field of the previously treated cancer (Chompret 2000, Hisada 1998). Approximately 24% of LFS cases result from a de novo, rather than inherited, mutation in the TP53 gene (Chompret 2000). This variant has been seen apparently mosaic. The variant is found in HEREDICANCER panel(s).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>p.V73RfsX76</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.4:c.216_217insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Neoplastic Syndromes, Hereditary</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0027672" Status="current" Type="CUI" />
            <XRef DB="MeSH" ID="D009386" Status="current" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GDX_AllTest_AllPolys_06102014</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2235139" SubmissionDate="2019-09-12" DateLastUpdated="2019-12-23" DateCreated="2019-12-23">
        <ClinVarSubmissionID localKey=":Chr.17_7579470_7579471_-_G|Orphanet:29073" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001132073" DateUpdated="2019-12-23" DateCreated="2019-12-23" Type="SCV" Version="1" SubmitterName="Xiao lab, Department of Pathology, Memorial Sloan Kettering Cancer Center" OrgID="507116" OrganizationCategory="clinic" OrgAbbreviation="Xiao-Path" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-08-31">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>somatic</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <NamePlatform>Hi-seq</NamePlatform>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="TestName">MSK-IMPACT-Heme</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="17" alternateAllele="G" referenceAllele="-" start="7579470" stop="7579471" variantLength="2" />
          </Location>
          <OtherNameList>
            <Name>p.V73Rfs*76</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Multiple myeloma</ElementValue>
            </Name>
            <XRef DB="Orphanet" ID="ORPHA29073" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6291744</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5050515" SubmissionDate="2022-10-07" DateLastUpdated="2022-10-22" DateCreated="2022-10-22">
        <ClinVarSubmissionID localKey="NM_000546.5:c.216dup|OMIM:151623" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002584666" DateUpdated="2022-10-22" DateCreated="2022-10-22" Type="SCV" Version="1" SubmitterName="St. Jude Molecular Pathology, St. Jude Children's Research Hospital" OrgID="506672" OrganizationCategory="laboratory" OrgAbbreviation="SJCRH-MP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The TP53 c.216dup (p.Val73ArgfsTer76) change inserts one nucleotide to cause a frameshift and the creation of a premature stop codon. This change is predicted to cause protein truncation or absence of the protein due to nonsense mediated decay and functional studies support a loss of p53 function (PMID: 28369373). That variant has been reported in individuals meeting clinical criteria for Li-Fraumeni syndrome (PMID: 1565143, internal data). It is absent in gnomAD v2.1.1 (http://gnomad.broadinstitute.org). In summary, this variant meets criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">St. Jude Assertion Criteria 2020</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/0uggzi4w/st._jude_assertion_criteria_2020.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.5:c.216dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="151623" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12131575</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1222008" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="338594|MedGen:C0085390" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000629790" DateUpdated="2024-02-14" DateCreated="2017-12-26" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20522432</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">1565143</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28369373</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Val73Argfs*76) in the TP53 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TP53 are known to be pathogenic (PMID: 20522432). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with osteosarcoma and breast cancer (PMID: 1565143, 28369373). This variant is also known as a 1-bp insertion at codons 71-72. ClinVar contains an entry for this variant (Variation ID: 182957). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.7579470_7579471insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085390" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5044475" SubmissionDate="2022-10-06" DateLastUpdated="2022-10-15" DateCreated="2022-10-15">
        <ClinVarSubmissionID localKey="NM_000546.6:c.216dup|Hereditary cancer-predisposing syndrome" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002582622" DateUpdated="2022-10-15" DateCreated="2022-10-15" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.6:c.216dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12130325</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5045037" SubmissionDate="2022-10-06" DateLastUpdated="2022-10-15" DateCreated="2022-10-15">
        <ClinVarSubmissionID localKey="NM_000546.6:c.216dup|OMIM:151623" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002583184" DateUpdated="2022-10-15" DateCreated="2022-10-15" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000546.6:c.216dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="151623" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12130325</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9142949" SubmissionDate="2024-04-22" DateLastUpdated="2024-05-01" DateCreated="2024-05-01">
        <ClinVarSubmissionID localKey="100055734|OMIM:151623" />
        <ClinVarAccession Accession="SCV004931857" DateUpdated="2024-05-01" DateCreated="2024-05-01" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TP53" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="17" alternateAllele="CG" referenceAllele="C" start="7579470" stop="7579470" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100055734</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="151623" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14395420</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9142949" TraitType="Disease" MappingType="XRef" MappingValue="151623" MappingRef="OMIM">
        <MedGen CUI="C1835398" Name="Li-Fraumeni syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="377492" TraitType="Disease" MappingType="Name" MappingValue="Neoplastic Syndromes, Hereditary" MappingRef="Preferred">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="511639" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5045037" TraitType="Disease" MappingType="XRef" MappingValue="151623" MappingRef="OMIM">
        <MedGen CUI="C1835398" Name="Li-Fraumeni syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1222008" TraitType="Disease" MappingType="XRef" MappingValue="C0085390" MappingRef="MedGen">
        <MedGen CUI="C0085390" Name="Li-Fraumeni syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4007350" TraitType="Disease" MappingType="XRef" MappingValue="CN221562" MappingRef="MedGen">
        <MedGen CUI="CN221562" Name="Breast and/or ovarian cancer" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2235139" TraitType="Disease" MappingType="Name" MappingValue="Multiple myeloma" MappingRef="Preferred">
        <MedGen CUI="C0026764" Name="Multiple myeloma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5044475" TraitType="Disease" MappingType="Name" MappingValue="Hereditary cancer-predisposing syndrome" MappingRef="Preferred">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5050515" TraitType="Disease" MappingType="XRef" MappingValue="151623" MappingRef="OMIM">
        <MedGen CUI="C1835398" Name="Li-Fraumeni syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="33404" TraitType="Disease" MappingType="Name" MappingValue="LI-FRAUMENI-LIKE SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C2675080" Name="Li-fraumeni-like syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

